Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 8/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MPI | P34949 | 1/20 | 0.32 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 2/20 | 0.31 |
| ▸ | PPARD | Q03181 | 2/20 | 0.31 |
| ▸ | PPARA | Q07869 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6404650 | 0.82 | PTGS2 (0.48) | PTGS2PTGS1KDM4EALDH1A1GAA | |
| SCHEMBL6404998 | 0.82 | PTGS2 (0.48) | PTGS2PTGS1KDM4EALDH1A1GAA | |
| SCHEMBL6683777 | 0.79 | PTGS2 (0.41) | PTGS2PTGS1 | |
| SCHEMBL6683202 | 0.76 | PTGS1 (0.41) | PTGS2PTGS1 | |
| SCHEMBL6680241 | 0.74 | PTGS2 (0.41) | PTGS2PTGS1 | |
| SCHEMBL6685269 | 0.74 | PTGS2 (0.44) | PTGS2PTGS1 | |
| SCHEMBL6408565 | 0.72 | PTGS2 (0.37) | PTGS2PTGS1PPARGPPARDPPARA | |
| SCHEMBL6405577 | 0.72 | PTGS2 (0.37) | PTGS2PTGS1PPARGPPARDPPARA | |
| SCHEMBL6682272 | 0.72 | PTGS1 (0.46) | PTGS2PTGS1PPARGPPARDPPARA | |
| SCHEMBL6408713 | 0.72 | PTGS2 (0.38) | PTGS2PTGS1KDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1274700-B1 | DIHYDROBENZOPYRANS, DIHYDROBENZOTHIOPYRANS, AND TETRAHYDROQUINOLINES FOR THE TREATMENT OF COX-2-MEDIATED DISORDERS | PHARMACIA CORP (US) | 2004-11-17 | — | — | EP | claimed |